Evidence map›Paper›PMID 25769654›Full record

ArticleStem cells translational medicine2015

Adipose-derived stem cells from diabetic mice show impaired vascular stabilization in a murine model of diabetic retinopathy.

Stephen M Cronk, Molly R Kelly-Goss, H Clifton Ray, Thomas A Mendel, Kyle L Hoehn, Anthony C Bruce, Bijan K Dey, Alexander M Guendel, Daniel N Tavakol, Ira M Herman and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cells translational medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 49 citations in OpenAlex.

  1. Review
  2. Cells · 2024
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Comparison of the Donor Age-Dependent andStem cells international · 2021
    Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Adult Stem Cell Therapeutics in Diabetic Retinopathy.International journal of molecular sciences · 2019
    Review
  17. Empowering Mesenchymal Stem Cells for Ocular Degenerative Disorders.International journal of molecular sciences · 2019
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Stephen M CronkDepartments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA.
Molly R Kelly-GossDepartments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA.
H Clifton RayDepartments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA.
Thomas A MendelDepartments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA.
Kyle L HoehnDepartments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA.
Anthony C BruceDepartments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA.
Bijan K DeyDepartments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA.
Alexander M GuendelDepartments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA.
Daniel N TavakolDepartments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA.
Ira M HermanDepartments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA.
Shayn M PeirceDepartments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA shayn@virginia.edu.
Paul A YatesDepartments of Biomedical Engineering, Pathology, Pharmacology, and Ophthalmology, University of Virginia, Charlottesville, Virginia, USA; Department of Developmental, Molecular and Chemical Biology and Center for Innovations in Wound Healing Research, School of Medicine, Tufts University, Boston, Massachusetts, USA.
University of Virginia · USTufts University · US

Funding

BASIC CARDIOVASCULAR RESEARCH TRAINING GRANTT32HL007284 · NHLBI · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI Brant E Isakson, Gary K Owens · 1985 to 2026
$19.6M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007267 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI GARCIA-BLANCO, MARIANO A. · 1985 to 2024
$13.4M
BIOTECHNOLOGY TRAINING PROGRAMT32GM008715 · NIGMS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI LAURIE, GORDON WILLIAM · 2000 to 2019
$6.6M
Adipose Stem Cells for Diabetic RetinopathyR01EY022063 · NEI · UNIVERSITY OF VIRGINIA · PI HERMAN, IRA M, PEIRCE-COTTLER, SHAYN · 2012 to 2015
$2.0M
ACC enzymes and protein acetylationR01DK101803 · NIDDK · UNIVERSITY OF VIRGINIA · PI HOEHN, KYLE LEE · 2014 to 2017
$1.4M
A new approach to the treatment of Retinopathy of PrematurityK08EY019533 · NEI · UNIVERSITY OF VIRGINIA · PI YATES, PAUL A. · 2009 to 2013
$959k
NEI NIH HHS K08 EY019533NEI NIH HHS R01 EY022063NHLBI NIH HHS T32 HL007284NIDDK NIH HHS R01 DK101803NIGMS NIH HHS T32 GM008715
6 · The paper itself

Abstract

Diabetic retinopathy is characterized by progressive vascular dropout with subsequent vision loss. We have recently shown that an intravitreal injection of adipose-derived stem cells (ASCs) can stabilize the retinal microvasculature, enabling repair and regeneration of damaged capillary beds in vivo. Because an understanding of ASC status from healthy versus diseased donors will be important as autologous cellular therapies are developed for unmet clinical needs, we took advantage of the hyperglycemic Akimba mouse as a preclinical in vivo model of diabetic retinopathy in an effort aimed at evaluating therapeutic efficacy of adipose-derived stem cells (mASCs) derived either from healthy, nondiabetic or from diabetic mice. To these ends, Akimba mice received intravitreal injections of media conditioned by mASCs or mASCs themselves, subsequent to development of substantial retinal capillary dropout. mASCs from healthy mice were more effective than diabetic mASCs in protecting the diabetic retina from further vascular dropout. Engrafted ASCs were found to preferentially associate with the retinal vasculature. Conditioned medium was unable to recapitulate the vasoprotection seen with injected ASCs. In vitro diabetic ASCs showed decreased proliferation and increased apoptosis compared with healthy mASCs. Diabetic ASCs also secreted less vasoprotective factors than healthy mASCs, as determined by high-throughput enzyme-linked immunosorbent assay. Our findings suggest that diabetic ASCs are functionally impaired compared with healthy ASCs and support the utility of an allogeneic injection of ASCs versus autologous or conditioned media approaches in the treatment of diabetic retinopathy.

Indexed as

Cell- and Tissue-Based TherapyStem Cell TransplantationAdipocytesAnimalsCulture Media, ConditionedDiabetes Mellitus, ExperimentalDiabetic RetinopathyDisease Models, AnimalMiceStem CellsCulture Media, ConditionedAdipose-derived stem cellsDiabetesDiabetic retinopathyPericyteStem cells

Identifiers

PMID25769654
PMCPMC4414213
OpenAlexW2076609872

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.